Exelixis logo

Exelixis

Exelixis works on discovering, developing, and commercializing therapies for the treatment of cancer

1566 employees · est. 1994 · Alameda, United States

VS
NewLink Genetics logo

NewLink Genetics

Now Lumos Pharma, Inc.

29 employees · est. 1999 · Ames, United States

Exelixis is the older company (1994 vs 1999); Exelixis is the larger of the two.

Side-by-Side Comparison

Exelixis NewLink Genetics
Founded
1994 older 1999
Headquarters
Alameda, United States Ames, United States
Employees
1566 larger 29
Industry
Biotechnology Biotechnology, Health Care, Health and Wellness
Funding Stage
IPO Series D
Total Funding
$340.26M $33.59M
Funding Rounds
8 4
Services
Drug Discovery, Medicine Development, Clinical Research, Cancer Treatment Solutions, Collaborative R&D Not tracked yet
Target Customers
Cancer Patients, Healthcare Providers, Research Institutions, Pharmaceutical Partners, Oncology Specialists Not tracked yet
Taxonomy
Cancer Therapy, Drug Discovery, Oncology, Biotech Sector, Commercialization, Innovative Treatments, Multi-platform Approach, Resiliency, Next-generation Treatments, Patient Focus, Tumor Treatment, Science Transformation, Employee Value, Cancer Research Bio-pharmaceutical, Immuno-oncology, Cancer Research, Drug Development, Patient-focused, Physician-scientists, Treatment Paradigm, Medical Innovation
Website
exelixis.com newlinkgenetics.com
Exelixis logo

About Exelixis

Exelixis, a pioneering entity in the Biotechnology industry, has been transforming the landscape of cancer treatment since its inception in 1994. Headquartered in the United States, the company operates with a fundamental commitment encapsulated in its slogan: "Exelixis works on discovering, develop...

NewLink Genetics logo

About NewLink Genetics

NewLink Genetics, now operating under the name Lumos Pharma, Inc., is a distinguished player in the biopharmaceutical industry. Founded in 1999, the company is headquartered in the United States. It focuses on the discovery, development, and commercialization of novel immuno-oncology products to tra...

We will tell you when either one moves

BounceWatch watches Exelixis and NewLink Genetics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Exelixis and NewLink Genetics — by email.

Frequently Asked Questions

Exelixis — Exelixis works on discovering, developing, and commercializing therapies for the treatment of cancer. NewLink Genetics — Now Lumos Pharma, Inc.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Exelixis has raised $340.26M while NewLink Genetics has raised $33.59M.
Exelixis and NewLink Genetics operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Exelixis with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Exelixis on 3 Jul 2026, and NewLink Genetics on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy